Welcome to our dedicated page for Cullinan Oncology SEC filings (Ticker: CGEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to gauge the clinical momentum behind Cullinan Oncology’s modular pipeline can mean sifting through immuno-oncology jargon scattered across dense SEC exhibits. Each 10-K risk factor or 8-K clinical update has language that only seasoned biotech lawyers enjoy. Stock Titan’s AI-powered analysis turns those pages into clear takeaways in minutes, letting you focus on whether CGEM’s next data read-out justifies a position.
Here’s where investors typically start:
- Cullinan Oncology annual report 10-K simplified – isolate trial timelines, cash runway and manufacturing commitments.
- Cullinan Oncology quarterly earnings report 10-Q filing – track R&D burn, collaboration revenue and milestone payments.
- Cullinan Oncology 8-K material events explained – decode interim clinical data and partnership announcements.
- Cullinan Oncology insider trading Form 4 transactions and Cullinan Oncology executive stock transactions Form 4 – monitor management confidence in real time.
- Cullinan Oncology proxy statement executive compensation – understand incentive alignment with pipeline success.
- Cullinan Oncology SEC filings explained simply – an AI snapshot for every document.
With real-time alerts, Cullinan Oncology Form 4 insider transactions real-time appear on your dashboard seconds after EDGAR posts. Our AI summary engine tags critical sections, answers natural questions like “understanding Cullinan Oncology SEC documents with AI” or “Cullinan Oncology earnings report filing analysis,” and links related disclosures automatically. Whether you need scenario modeling for a financing event or quick context before an oncology conference, Stock Titan provides complete coverage, accuracy, and the clarity busy professionals expect.
Cullinan Therapeutics (CGEM) reported a Q3 2025 net loss of $50.6M as operating expenses rose with pipeline investment. Research and development was $41.97M and general and administrative was $13.63M, offset partly by $5.09M of interest income.
Liquidity remains strong with cash and cash equivalents of $103.3M, short‑term investments of $229.3M, and long‑term investments of $140.0M as of September 30, 2025. Management states these resources are sufficient to fund operations through at least the next twelve months. The company also has an at‑the‑market program with $85.6M capacity remaining.
Pipeline updates: Cullinan licensed velinotamig from Genrix with a $20.0M upfront fee recorded in R&D. Zipalertinib, co‑developed with Taiho, met the primary endpoint in a pivotal Phase 2b; following a positive Type B pre‑NDA meeting, Taiho plans a rolling NDA submission by year‑end 2025. Subsequent to quarter end, Cullinan decided not to pursue further development of CLN‑619 and CLN‑617. Common shares outstanding were 59,076,259 as of October 31, 2025.
Cullinan Therapeutics (CGEM) reported quarterly results and disclosed liquidity details. As of September 30, 2025, cash, cash equivalents, short- and long-term investments, and interest receivable totaled $475.5 million. The company stated its cash resources are expected to provide runway into 2029 under its new operating plan.
The press release with results was furnished as Exhibit 99.1. The disclosure was provided as supplemental information and designated as furnished, not filed, under the Exchange Act.
Cullinan Therapeutics reported new Phase 1 data for CLN-049 in relapsed/refractory AML and MDS, to be presented at the ASH Annual Meeting in December. As of the June 2025 cutoff, 40 patients were enrolled and 29 AML patients were efficacy evaluable.
In AML at target doses ≥6 μg/kg (n=23), CLN-049 showed a CRc rate of 30% and an ORR of 57%. At 12 μg/kg (n=13), the CRc rate was 31% and ORR was 69%. Among nine patients achieving bone marrow blasts <5%, three were MRD negative by flow cytometry; relapse was not observed in MRD-negative patients, and one patient has remained on study for >6 months. Responses were observed regardless of baseline genetic risk, including four responses (2 CRh, 2 MLFS) among five TP53‑mutated AML patients treated at 12 μg/kg.
Safety findings indicate a manageable profile in 40 patients: the most common TEAEs were CRS (40%) and infusion-related reaction (35%). All CRS events were Grade 1–2, with one Grade 1 ICANS; none led to discontinuation. Grade ≥3 TEAEs >10% included febrile neutropenia and white blood cell count decrease (17.5% each), and pneumonia (12.5%). Dose escalation is ongoing.
Cullinan Therapeutics (CGEM): Reporting persons associated with Lynx1 Capital Management disclosed an open‑market purchase of 165,667 shares of common stock on 10/28/2025 at a weighted average price of $8.4005, executed across multiple trades ranging from $8.035 to $8.50.
Following the transaction, they report 8,963,500 shares beneficially owned on an indirect basis through Lynx1 Master Fund LP. The filing notes a standard disclaimer of beneficial ownership except to the extent of pecuniary interest.
Cullinan Therapeutics (CGEM): Lynx1-affiliated reporting persons disclosed open‑market purchases of Common Stock across four days, increasing their indirect holdings. Following the most recent transaction, beneficial ownership stood at 8,797,833 shares, held indirectly through Lynx1 Master Fund LP as described in the filing.
- 10/14/2025: 15,032 shares at a weighted avg price of $7.587 (purchases ranged $7.50–$7.68).
- 10/15/2025: 51,500 shares at $7.9427 (range $7.88–$8.00).
- 10/16/2025: 150,000 shares at $8.855 (range $8.68–$9.22).
- 10/17/2025: 32,217 shares at $7.8395 (range $7.78–$7.85).
The filing lists the transactions as purchases and notes the indirect ownership structure via Lynx1 Capital Management LP and related entities.
Lynx1 Capital Management LP and affiliated reporting person Weston Nichols disclosed purchases of Cullinan Therapeutics, Inc. (CGEM) common stock across three days. On
Cullinan Therapeutics, Inc. (CGEM) Form 3 shows that Lynx1 Capital Management LP and individual Weston Nichols reported an initial beneficial ownership event dated
Cullinan Therapeutics received a Schedule 13G amendment showing Lynx1 Capital Management LP and Weston Nichols together beneficially own 8,549,084 shares of common stock, representing
Cullinan Therapeutics disclosed that Lynx1 Capital Management LP and Weston Nichols collectively report beneficial ownership of 4,400,842 shares, representing 7.5% of the outstanding common stock based on 59,014,667 shares outstanding as of April 30, 2025. The holdings are reported as shared voting and dispositive power, with no sole voting or dispositive power indicated.
This Schedule 13G filing identifies the investment manager (Lynx1) and Mr. Nichols as reporting persons and states the shares are held by the Lynx1 Master Fund. The filing includes a certification that the position was not acquired to change or influence control of the company.
FAQ
What is the current stock price of Cullinan Oncology (CGEM)?
What is the market cap of Cullinan Oncology (CGEM)?
